Strong US dollar hurts Swiss pharmaceutical company Novartis with 32-per cent drop in Q2 profit + MORE Jul 21st

There are more investment options in Canada than you can shake a stick at! Stay on top of the best returns right here.
Latest News
 TSE

Why Canada’s big investment banks don’t suffer like global rivals + MORE Apr 1st

During the crisis, many global investment banks were dinged for having far too much financial leverage .... More »

Aurora Cannabis Announces Financial Results for the Fourth Quarter and 2019 Fiscal Year - Canada NewsWire + MORE Sep 11th

Aurora Cannabis Announces Financial Results for the Fourth Quarter and 2019 Fiscal Year  Canada NewsWireGenerates Net Revenue of $98.9 Million, Up 52% From Prior Quarter Cannabis Net Revenue Increases 61% to $94.6 Million From Prior Quarter Reports Gross ...View full coverage on Google New.... More »
 resp

The State of Commercial Real Estate in Canada Jan 22nd

From a transactional standpoint, particularly for investments, it was one of the slowest years we’ve had in a long time. Inflation and subsequent interest rate increases prompted a sense of uncertainty across global real estate markets. Canadians spent most of the year asking whether interest .... More »

Weekend Reading – Rich couples, frugalista, let’s get blunt, dogs are optional and more + MORE Sep 11th

Learn, save, invest and prosper by subscribing to My Own Advisor. Welcome to some fine Weekend Reading friends.  Seems like the 40 Deg. C heat (with humidity) in Ottawa is now over for the summer but some good weather will remain I think for weeks to come.  Hopefully the weather and other things a.... More »

The best GIC rates in Canada for 2025 Jan 20th

GIC comparison tool Find the best and most up-to-date GIC rates in Canada using the comparison tool below. Plus, use the filters to assess your estimated rate of return based on the size of your balance. Why trust us MoneySense is an award-winning magazine, helping Canadians navigat.... More »
TOKYO – Toshiba’s chief executive resigned Tuesday to take responsibility for doctored books that inflated profits at the Japanese technology manufacturer by 152 billion yen ($1.2 billion) over several years.
Toshiba Corp. acknowledged a systematic coverup, which began in 2008. Various parts of the Japanese company’s sprawling business including computer chips and personal computers were struggling financially, but top managers set unrealistic earnings targets under the banner of “challenge,” and subordinates faked results.
On top of its struggles in electronics, Tokyo-based Toshiba’s prospects in nuclear power, one of its core businesses, were shaken after the 2011 Fukushima disaster set off public fears about reactor safety, making new nuclear plants unlikely in Japan. All 48 of the nation’s working reactors are now offline.
Bowing deeply before flashing cameras at a news conference, CEO Hisao Tanaka kept his head lowered for nearly half a minute in a gesture meant to convey deep shame and contrition…

Continue Reading On canadianbusiness.com »

The best of the web on money, markets and all things financial, as chosen daily by Globe and Mail personal finance columnist Rob Carrick

Continue Reading On theglobeandmail.com »

Beware the hype of the next big deal

– theglobeandmail.com

The financial crisis was supposed to teach us about falling for resource boom hype, yet CEOs make the same mistakes over and over again

Continue Reading On theglobeandmail.com »

BERLIN – Swiss-based pharmaceutical giant Novartis’ second-quarter net income dropped 32 per cent over the same quarter last year, brought down primarily by poor performance from associated companies and negative effects of a strong U.S. dollar, the company said Tuesday
Net income was $1.856 billion, down from $2.723 billion in the same quarter in 2014. Net sales were down 5 per cent to $12.694 billion and earnings per share from continuing operations dropped to $0.77 from $1.11 last year.
Nevertheless, CEO Joseph Jimenez said the company had a strong quarter for innovation with the U.S. approval and launch of two new drug products — heart failure drug Entresto and multiple sclerosis therapy drug Glatopa — and confirmed its full-year guidance.
Group sales are expected to grow by mid-single digits and operating income is expected to grow ahead of sales at a high-single-digit rate, Novartis has said.
“We are confident we will deliver on our priorities for the year,” Jimenez said…

Continue Reading On canadianbusiness.com »

Drug makers lead European stocks slightly lower; crude oil continues to skid on oversupply concerns

Continue Reading On theglobeandmail.com »

Share

PinIt
Compare insurance quotes through Kanetix.ca - save time and money!